Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PSE bill moves in legislative queue

This article was originally published in The Tan Sheet

Executive Summary

Sen. Dianne Feinstein's, D-Calif., Combat Methamphetamine Enhancement Act, S. 256, moves to the Senate floor for debate. The legislation would require retailers selling cold products with methamphetamine precursors - pseudoephedrine and ephedrine - to train employees on compliance with sales restrictions required by a 2006 law. The Judiciary Committee on March 5 approved the bill, which will be considered by the full Senate on a date to be determined, staff said March 23 (1"The Tan Sheet" March 9, 2009, p. 8)

You may also be interested in...



Capitol Hill In Brief

Omnibus stalls: Congress March 6 extends a continuing resolution to fund most federal agencies through March 11 at fiscal 2008 levels while the House and Senate continue deliberating an omnibus package covering the rest of fiscal 2009. The previous continuing resolution expired March 6 (1"The Tan Sheet" Oct. 6, 2008, p. 9). The House Feb. 25 passed a $410 billion dollar omnibus package, H.R. 1105, including $2.6 billion for FDA, but the bill has stalled in the Senate (2"The Tan Sheet" March 2, 2009, p. 9). Votes are expected March 9 on Republican amendments and March 10 on the Senate's version of the omnibus covering federal agencies other than the departments of Defense and Homeland Security, which were funded in separate legislation Congress enacted in 2008

The Factory Floor: Biocon Celebrates Malaysian Insulin Plant Clearance

Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.

Lannett Rolls Out US Adderall XR Rival

Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.

Topics

UsernamePublicRestriction

Register

PS102758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel